Ruben A. Mesa, MD:This is a 39-year-old gentleman with polycythemia vera. Specifically, he presented with significant erythrocytosis without leukocytosis or thrombocytosis. He had a bone marrow aspirate and biopsy done, which showed morphologic features consistent with polycythemia vera, as well as the presence of theJAK2mutation. He had a normal karyotype. He did not have a significant increase in fibrosis; he just had 1+ fibrosis. So, he met the WHO 2016 criteria for a diagnosis of polycythemia vera. Now, in managing a patient like this, we have to first assess their risk. And the risk factors for polycythemia vera that we consider are an age greater than 60 and prior thrombotic events or hemorrhagic events, which this individual has not had. However, this individual does have significant cardiovascular risk factorssome hypertension, some diabetes—and those are additional factors. So, in my practice, I would consider this individual as having an intermediate-risk polycythemia vera.
The goals for managing a patient like this are several-fold. They are really aimed at trying to prevent thrombosis or bleeding, and they include, certainly, trying to manage his cardiovascular risk factors. So, individuals are managed on a basis of phlebotomy to control the hematocrit. Ideally, in 2017, we know our targets would be a hematocrit of less than 45%, as well as the use of low-dose aspirin: 81 mg in the United States but 100 mg or less, given the different formulations, around the world. We’ll be monitoring the patient to be sure that we’re keeping up with their phlebotomyit needs to keep the hematocrit under 45%—as well as making certain they’re not having vascular events, they’re not developing splenomegaly, and they’re not developing symptoms or other difficult disease features.
This patient began on phlebotomies and, after 3 months, is having difficulties with phlebotomy, having a variety of side effects: fatigue, dizziness, and other problematic issues. So, the individual has begun on hydroxyurea as a cytoreductive therapy. The need for phlebotomies continues, and the dose of hydroxyurea is increased further from 1000 mg to 1500 mg a day.
Transcript edited for clarity.
January 2015
April 2015
July 2015
October 2015
January 2016
Connecting Spleen Volume Reduction to Survival Outcomes in MF
April 21st 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More